List of NeuroSearch announcements from January 2012 to February 2013
2/8/2013 4:24 AM EST
NeuroSearch A/S
Company Announcement
List of NeuroSearch announcements from January 2012 to February 2013
Announcement
08.02.2013
In accordance with section 27b of Consolidated Act about Securities Trading
etc., we hereby issue a complete list of NeuroSearch announcements from January
2012 to 8 February 2013. All announcements are available under the IR section
of the company's website: www.neurosearch.com.
Date No. Title
--------------------------------------------------------------------------------
26.01.2012 01-12 Notice convening Extraordinary General Meeting in NeuroSearch
A/S
--------------------------------------------------------------------------------
10.02.2012 02-12 NeuroSearch announces a change to the date of the Annual
General Meeting 2012
--------------------------------------------------------------------------------
10.02.2012 03-12 NeuroSearch – Financial calendar for 2012
--------------------------------------------------------------------------------
20.02.2012 04-12 Report on Extraordinary General Meeting in NeuroSearch A/S
--------------------------------------------------------------------------------
22.02.2012 05-12 Release date for the financial statements 2011 for
NeuroSearch A/S and subsequent telephone conference
--------------------------------------------------------------------------------
28.02.2012 06-12 NeuroSearch announces the company's Annual Report 2011
--------------------------------------------------------------------------------
28.02.2012 07-12 List of NeuroSearch announcements from January 2011 to
February 2012
--------------------------------------------------------------------------------
16.03.2012 08-12 Notice convening the Annual General Meeting of NeuroSearch
A/S
--------------------------------------------------------------------------------
10.04.2012 09-12 NeuroSearch A/S provides update on the process to secure
financing to complete the Huntexil® development programme
--------------------------------------------------------------------------------
10.04.2012 10-12 Report on Annual General Meeting held in NeuroSearch A/S
--------------------------------------------------------------------------------
25.04.2012 11-12 NeuroSearch A/S – Q1 report 2012 and update on the company's
activities
--------------------------------------------------------------------------------
10.05.2012 12-12 Major shareholder announcement / UBS AG
--------------------------------------------------------------------------------
14.05.2012 13-12 Major shareholder announcement / UBS AG
--------------------------------------------------------------------------------
23.05.2012 14-12 NeuroSearch advises of charges filed against the company for
alleged share price manipulation in 2010
--------------------------------------------------------------------------------
28.05.2012 15-12 NeuroSearch A/S reports conclusions from the Multiple
Ascending Dose study (MAD) with Huntexil®
--------------------------------------------------------------------------------
22.06.2012 16-12 NeuroSearch advises of the Danish Medicines Agency's
conclusion on the TIPO-1 tesofensine study inspection
--------------------------------------------------------------------------------
27.06.2012 17-12 NeuroSearch A/S changes the Executive Management
--------------------------------------------------------------------------------
30.08.2012 18-12 NeuroSearch A/S – Interim report for H1 2012
--------------------------------------------------------------------------------
31.08.2012 19-12 NeuroSearch A/S reports change of employee elected Board
members
--------------------------------------------------------------------------------
31.08.2012 20-12 NeuroSearch A/S signs agreements regarding transfer of
research collaboration with Janssen Pharmaceutica, NV and
other projects to Aniona
--------------------------------------------------------------------------------
27.09.2012 21-12 NeuroSearch A/S and Teva Pharmaceutical Industries Ltd. sign
Huntexil® asset transfer agreement conditional upon
NeuroSearch shareholder approval
--------------------------------------------------------------------------------
27.09.2012 22-12 Notice convening Extraordinary General Meeting in NeuroSearch
A/S
--------------------------------------------------------------------------------
23.10.2012 23-12 Report on Extraordinary General Meeting in NeuroSearch A/S
--------------------------------------------------------------------------------
25.10.2012 24-12 NeuroSearch A/S closes the sale of Huntexil® to Teva
Pharmaceutical Industries Ltd. and adjusts the expectations
to the full-year result
--------------------------------------------------------------------------------
15.11.2012 25-12 NeuroSearch A/S – Interim report for the period
January-September 2012
--------------------------------------------------------------------------------
10.12.2012 26-12 Notice convening Extraordinary General Meeting in NeuroSearch
A/S
--------------------------------------------------------------------------------
04.01.2013 01-13 Report on Extraordinary General Meeting in NeuroSearch A/S
--------------------------------------------------------------------------------
08.01.2013 02-13 NeuroSearch – Financial calendar for 2013
--------------------------------------------------------------------------------
21.01.2013 03-13 NeuroSearch A/S – Annual General Meeting 2013
--------------------------------------------------------------------------------
28.01.2013 04-13 NeuroSearch A/S reports change of employee elected Board
member
--------------------------------------------------------------------------------
01.02.2013 05-13 Release date for the financial statements 2012 for
NeuroSearch A/S and subsequent telephone conference
--------------------------------------------------------------------------------
04.02.2013 06-13 NeuroSearch A/S sells land and building
--------------------------------------------------------------------------------
08.02.2013 07-13 NeuroSearch A/S – Annual Report 2012
--------------------------------------------------------------------------------
René Schneider
CEO
Contact person
René Schneider, CEO, telephone: +45 4460 8700 or +45 2911 2097
About NeuroSearch
NeuroSearch A/S (NEUR) is listed on NASDAQ OMX Copenhagen A/S. The company’s
product pipeline comprises ordopidine and seridopidine, which have both
completed phase I studies, as well as tesofensine, which has completed phase
II, and NS2359 which has completed phase I. All drug candidates exert their
effect in the central nervous system.